Nath Bio-Genes (India) Limited files substantial acquisition disclosure under SEBI Takeover Code

M&A / JV 19 Jun 2026 · Announced· ✓ Verified

Nath Bio-Genes (India) Limited has submitted a mandatory disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as required when a party acquires shares or voting rights exceeding specified thresholds. The disclosure was filed with the NSE. The filing triggers transparency requirements and may necessitate an open offer if the acquirer crosses the 26% threshold or if specified conditions are met under the Takeover Code.

Why it mattersThe filing indicates a threshold acquisition (typically 5% or more) has occurred or is being announced; partners must review the detailed disclosure for acquirer identity, shareholding pattern post-transaction, and any open offer obligations under Regulation 38 of the Takeover Code.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals